ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 08 4:00PM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
bigsur25 bigsur25 5 minutes ago
Please do
MONI
delerious1 delerious1 5 minutes ago
There's much that could be better...too bad so sad
Investor082 Investor082 5 minutes ago
I will check in with you on this post as LP announces financing or raises money post UK approval, resulting in dilution again. And when no big pharma injects cash in NWBO in Q1, 2025.
NWBO
OMOLIVES OMOLIVES 5 minutes ago
lol...
DROR
Maxinvestor89 Maxinvestor89 6 minutes ago
That's a Question I ask myself for a few stocks (RDAR with Mexedia is one)

The only thing I significant see is shareholders base and good liquidity (Yes incoming shareholders can't sell for a while, but at least when they'll be able to, they know that there will likely be buyers, and
RDAR
Testpilot Testpilot 6 minutes ago
That’s what Walrus and I are thinking 🤔
CRTG
GrandAdmiralThrawn GrandAdmiralThrawn 8 minutes ago
Same, I, doing the same if this drops, I'm buying way more
HMBL
Kool Aid Man Kool Aid Man 8 minutes ago
"A pump and dump is when the stock returns to its original price after news fails to be true"--Where did you come up with this nutty definition?
On the contrary-- a "pump and dump is a form of securities fraud that involves artificially inflating the price of an owned stock through false and
SPZI
bas2020 bas2020 8 minutes ago
Just a bunch of FUD nonsense from you. That's all we've come to expect from you and your colleagues. 👿☠️

With the large amount of FUD today, I'm thinking we must be getting very close to approval news.
NWBO
Rodney5 Rodney5 10 minutes ago
DCBill, you ask why would the (MAGA) courts (as in SCOTUS) suddenly start deciding in favor of shareholders??

The Plaintiffs brought the wrong lawsuit.

Director Lockhart Regulator, and Director Lockhart Conservator. Strangely enough, Holding both positions as Regulato
APA
Mr. Zen Mr. Zen 10 minutes ago
This shell was primo when it was up for sale, low float and no debt... Now the new owners are here lets see what they can do, they have the money and knowledge behind them, but public company savvy they may be lacking.
LEEN
MadScholar1 MadScholar1 11 minutes ago
You seem very certain that there was no two-step process. If Visolis/LCY had a deal with Eno going back to 2017, and submitted a bid before the auction was announced, de facto, a two-step stalking horse process was initiated. The fact that KKR entered with angel money to back LCY is an additional fa
KKR
misterfishman misterfishman 11 minutes ago
Don't respond to him bro just ignore him.
IGPK
hedge_fun hedge_fun 11 minutes ago
Bet there is a good reason for that.

Wonder why the company hasn’t stated the device found treasure, said what the treasure is, and operations to salvage it have begun.

Are they not confident in the data?

Why would they be excavating if the data didn’t
SFRX
Investor082 Investor082 12 minutes ago
Spoken like a true bag holder! There will be no non dilutive cash injection from any partnership, but wait for LP to give you that bad news post approval. It will be another fluff like Roswell Park and she will utilize the opportunity to dilute the hell out of the shareholders. Otherwise there is no
NWBO
dinogreeves dinogreeves 12 minutes ago
The big day is Tuesday and Wednesday, tomorrow is just a preview of the main attraction.
SMCI
Top Penny Top Penny 12 minutes ago
This is looking interesting, they just keep adding big hitters, might jump back in.
MONI
Lifetime Lifetime 13 minutes ago
You are the one assed out.... you look it up
gdog gdog 15 minutes ago
ok me and the wife are trying to guess which young lady is Wayne's daughter I say the one with the pokadot head scarf and big smile to the center left
wifes guess is the back row fourth from the left
ya'll can see Wayne pic in his profile
tdbowieknife tdbowieknife 15 minutes ago
BLQC is the stock that OPTI's "new CEO" Gregg Boehmer and Brett Rosen are involved with together... I posted some stuff over there.

And I was wondering too if the receiver new about the SOS filings.

.

Buyer Beware
Pump and Dump
http://i
BLQC OPTI
bas2020 bas2020 15 minutes ago
The simplest response that fits the bill is the best one. 👿☠️
NWBO
mascale mascale 16 minutes ago
Affirmation accepted.
HIRU
nowwhat2 nowwhat2 16 minutes ago
Uh, sorry but I'm afraid I can't quite understand what you're asking there.....plus actually nor whether anyone would ?
qualityincolor qualityincolor 16 minutes ago
Yeah i thought so
XRPUSD
Hardazoak Hardazoak 17 minutes ago
But you can't prove it gitreal, so stop with the lies.
AABB

Your Recent History

Delayed Upgrade Clock